 Glucosides
"Glucosides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D005960
|
| MeSH Number(s) |
D09.408.348
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Glucosides".
Below are MeSH descriptors whose meaning is more specific than "Glucosides".
This graph shows the total number of publications written about "Glucosides" by people in this website by year, and whether "Glucosides" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 | | 2004 | 1 | 0 | 1 | | 2007 | 0 | 1 | 1 | | 2012 | 2 | 2 | 4 | | 2015 | 1 | 0 | 1 | | 2016 | 0 | 1 | 1 | | 2017 | 4 | 2 | 6 | | 2018 | 4 | 1 | 5 | | 2019 | 2 | 2 | 4 | | 2020 | 2 | 3 | 5 | | 2021 | 1 | 0 | 1 | | 2022 | 0 | 6 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Glucosides" by people in Profiles.
-
Warshaw EM, Xiong M, DeKoven JG, Taylor JS, Belsito DV, Reeder MJ, Adler BL, Pratt MD, Atwater AR, Maibach HI, Silverberg JI, Yu J, Botto N, Fowler JF, Houle MC, Mowad CM, Dunnick CA, DeLeo VA. Co-reactivity of glucosides: Retrospective analysis of North American Contact Dermatitis Group Data 2019-2020. Contact Dermatitis. 2023 02; 88(2):153-156.
-
Sen T, Scholtes R, Greasley PJ, Cherney DZI, Dekkers CCJ, Vervloet M, Danser AHJ, Barbour SJ, Karlsson C, Hammarstedt A, Li Q, Laverman GD, Bjornstad P, van Raalte DH, Heerspink HJL. Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND. Diabetes Obes Metab. 2022 08; 24(8):1578-1587.
-
Kurtz R, Libby A, Jones BA, Myakala K, Wang X, Lee Y, Knoer G, Lo Cascio JN, McCormack M, Nguyen G, Choos END, Rodriguez O, Rosenberg AZ, Ranjit S, Albanese C, Levi M, Ecelbarger CM, Shepard BD. Empagliflozin Treatment Attenuates Hepatic Steatosis by Promoting White Adipose Expansion in Obese TallyHo Mice. Int J Mol Sci. 2022 May 18; 23(10).
-
Warshaw EM, Xiong M, Atwater AR, DeKoven JG, Pratt MD, Maibach HI, Taylor JS, Belsito DV, Silverberg JI, Reeder MJ, Zug KA, Sasseville D, Fowler JF, DeLeo VA, Houle MC, Dunnick CA. Patch testing with glucosides: The North American Contact Dermatitis Group experience, 2009-2018. J Am Acad Dermatol. 2022 Nov; 87(5):1033-1041.
-
Gr?nert SC, Derks TGJ, Adrian K, Al-Thihli K, Ballhausen D, Bidiuk J, Bordugo A, Boyer M, Bratkovic D, Brunner-Krainz M, Burlina A, Chakrapani A, Corpeleijn W, Cozens A, Dawson C, Dhamko H, Milosevic MD, Eiroa H, Finezilber Y, Moura de Souza CF, Garcia-Jim?nez MC, Gasperini S, Haas D, H?berle J, Halligan R, Fung LH, H?rbe-Blindt A, Horka LM, Huemer M, U?ar SK, Kecman B, Kilavuz S, Kriv?n G, Lindner M, L?sebrink N, Makrilakis K, Mei-Kwun Kwok A, Maier EM, Maiorana A, McCandless SE, Mitchell JJ, Mizumoto H, Mundy H, Ochoa C, Pierce K, Fraile PQ, Regier D, Rossi A, Santer R, Schuman HC, Sobieraj P, Spenger J, Spiegel R, Stepien KM, Tal G, Tan?ek MZ, Torkar AD, Tchan M, Thyagu S, Schrier Vergano SA, Vucko E, Weinhold N, Zsidegh P, Wortmann SB. Efficacy and safety of empagliflozin in glycogen storage disease type Ib: Data from an international questionnaire. Genet Med. 2022 08; 24(8):1781-1788.
-
Tommerdahl KL, Nelson RG, Bjornstad P. Dapagliflozin in young people with type 2 diabetes. Lancet Diabetes Endocrinol. 2022 05; 10(5):303-304.
-
Cherney DZI, Bjornstad P, Perkins BA, Rosenstock J, Neubacher D, Marquard J, Soleymanlou N. Kidney Effects of Empagliflozin in People with Type 1 Diabetes. Clin J Am Soc Nephrol. 2021 11; 16(11):1715-1719.
-
Rasouli N. An Escape From Diabetes. J Clin Endocrinol Metab. 2020 09 01; 105(9).
-
Bonaca MP, Wiviott SD, Zelniker TA, Mosenzon O, Bhatt DL, Leiter LA, McGuire DK, Goodrich EL, De Mendonca Furtado RH, Wilding JPH, Cahn A, Gause-Nilsson IAM, Johanson P, Fredriksson M, Johansson PA, Langkilde AM, Raz I, Sabatine MS. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation. 2020 08 25; 142(8):734-747.
-
Cahn A, Raz I, Bonaca M, Mosenzon O, Murphy SA, Yanuv I, Rozenberg A, Wilding JPH, Bhatt DL, McGuire DK, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Jermendy G, Hadjadj S, Langkilde AM, Sabatine MS, Wiviott SD, Leiter LA. Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. Diabetes Obes Metab. 2020 08; 22(8):1357-1368.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|